{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:29:15Z","timestamp":1790306955515,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with multiple sclerosis (MS) often receive disease-modifying therapies (DMTs) that can expose them to reactivation of potential occult hepatitis B virus (HBV) infection (pOBI). We aimed to evaluate the MS Centers behavior regarding HBV screening and prophylaxis in a large cohort of MS patients receiving anti-CD20 or cladribine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective, multicentric study recruiting Italian MS patients treated with rituximab, ocrelizumab and cladribine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 931 MS patients from 15 centers. All but 38 patients performed a complete HBV screening. Patients\u2019 age\u2009&gt;\u200950\u00a0years was significantly associated with no history of vaccination and HBsAb titres\u2009&lt;\u2009100 mIU at baseline (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). No significant correlation was found between post-vaccination HBsAb titres and type of treatment (<jats:italic>p<\/jats:italic>\u2009=\u20090.5), pre-or post-therapy vaccination (<jats:italic>p<\/jats:italic>\u2009=\u20090.2) and number of previous DMTs (<jats:italic>p<\/jats:italic>\u2009=\u20090.2). Among pOBI patients (<jats:italic>n<\/jats:italic>\u2009=\u200953), 21 received antiviral prophylaxis, while only 13 had HBV DNA monitoring and 19 patients neither monitored HBV DNA nor received prophylaxis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Baseline HBV screening in patients receiving anti-CD20 and cladribine is a consolidated practice. Nonetheless, HBV vaccination coverage is still lacking in such population and age is a significant factor associated with low HBV protection. Rituximab, ocrelizumab and cladribine did not impair HBV vaccine response. Almost 35% of pOBI patients fail to receive HBVr prevention. Management of HBV prophylaxis could be improved in MS patients and further prospective studies are needed to assess the effectiveness of prophylactic strategies in such patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-022-11009-x","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T18:02:59Z","timestamp":1644861779000},"page":"3301-3307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study"],"prefix":"10.1007","volume":"269","author":[{"given":"Antonio Riccardo","family":"Buonomo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3989-2520","authenticated-orcid":false,"given":"Giulio","family":"Viceconte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cavalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia Teresa","family":"Maniscalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Nociti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Radaelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Buscarinu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Paolicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Gajofatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Annovazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pinardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Di Filippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Cordioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Zappulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Scotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Luca","family":"Spiezia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Petruzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Brescia Morra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Solaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Gasperini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Moccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Lanzillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Raising Italian Researchers in Multiple Sclerosis (RIREMS) study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"11009_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","volume":"18","author":"MT Wallin","year":"2019","unstructured":"Wallin MT, Culpepper WJ, Nichols E et al (2019) Global, regional, and national burden of multiple sclerosis 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18:269\u2013285. https:\/\/doi.org\/10.1016\/S1474-4422(18)30443-5","journal-title":"Lancet Neurol"},{"issue":"38","key":"11009_CR2","first-page":"473","volume":"383","author":"MA Battaglia","year":"2016","unstructured":"Battaglia MA, Bezzini D (2016) (2016) Estimated prevalence of multiple sclerosis in Italy in 2015. Neurol Sci 383(38):473\u2013479","journal-title":"Neurol Sci"},{"key":"11009_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.106451","volume":"201","author":"M Adamczyk-Sowa","year":"2021","unstructured":"Adamczyk-Sowa M, Mado H, Kubicka-B\u0105czyk K et al (2021) SARS-CoV-2\/COVID-19 in multiple sclerosis patients receiving disease-modifying therapy. Clin Neurol Neurosurg 201:106451. https:\/\/doi.org\/10.1016\/j.clineuro.2020.106451","journal-title":"Clin Neurol Neurosurg"},{"key":"11009_CR4","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","volume":"384","author":"C Tr\u00e9po","year":"2014","unstructured":"Tr\u00e9po C, Chan HLY, Lok A (2014) Hepatitis B virus infection. Lancet 384:2053\u20132063","journal-title":"Lancet"},{"key":"11009_CR5","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jhep.2008.07.014","volume":"49","author":"G Raimondo","year":"2008","unstructured":"Raimondo G, Allain J-P, Brunetto MR et al (2008) Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 49:652\u2013657. https:\/\/doi.org\/10.1016\/j.jhep.2008.07.014","journal-title":"J Hepatol"},{"key":"11009_CR6","unstructured":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection q"},{"key":"11009_CR7","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1080\/14712598.2016.1177017","volume":"16","author":"M Vigan\u00f2","year":"2016","unstructured":"Vigan\u00f2 M, Serra G, Casella G et al (2016) Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders. Expert Opin Biol Ther 16:917\u2013926","journal-title":"Expert Opin Biol Ther"},{"key":"11009_CR8","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1111\/1756-185X.13582","volume":"22","author":"Y Chen","year":"2019","unstructured":"Chen Y, Chen H, Huang W et al (2019) Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: a long-term, real-world observation. Int J Rheum Dis 22:1756\u20131785. https:\/\/doi.org\/10.1111\/1756-185X.13582","journal-title":"Int J Rheum Dis"},{"key":"11009_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ofid\/ofy356","volume":"6","author":"MR Ciardi","year":"2019","unstructured":"Ciardi MR, Iannetta M, Zingaropoli MA et al (2019) Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis. Open Forum Infect Dis 6:1\u20133. https:\/\/doi.org\/10.1093\/ofid\/ofy356","journal-title":"Open Forum Infect Dis"},{"key":"11009_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018948","author":"AR Buonomo","year":"2020","unstructured":"Buonomo AR, Scotto R, Coppola C et al (2020) Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort). Med (United States). https:\/\/doi.org\/10.1097\/MD.0000000000018948","journal-title":"Med (United States)"},{"key":"11009_CR11","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","volume":"24","author":"M Mikulska","year":"2018","unstructured":"Mikulska M, Lanini S, Gudiol C et al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect 24:S71\u2013S82","journal-title":"Clin Microbiol Infect"},{"key":"11009_CR12","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ et al (2018) Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67:1560\u20131599. https:\/\/doi.org\/10.1002\/hep.29800","journal-title":"Hepatology"},{"key":"11009_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0140-6736(05)64642-9","volume":"348","author":"DP Busuttil","year":"1996","unstructured":"Busuttil DP, Chasty RC, Fraser M et al (1996) Delayed reactivation of hepatitis B infection after cladribine [8]. Lancet 348:129","journal-title":"Lancet"},{"key":"11009_CR14","unstructured":"Bollettino Seieva. https:\/\/www.epicentro.iss.it\/epatite\/Bollettino-Seieva. Accessed 14 Feb 2021"},{"key":"11009_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102439","volume":"45","author":"JR Ciotti","year":"2020","unstructured":"Ciotti JR, Valtcheva MV, Cross AH (2020) Effects of MS disease-modifying therapies on responses to vaccinations: a review. Mult Scler Relat Disord 45:102439. https:\/\/doi.org\/10.1016\/j.msard.2020.102439","journal-title":"Mult Scler Relat Disord"},{"key":"11009_CR16","first-page":"231","volume-title":"Handbook of Clinical Neurology","author":"DS Goodin","year":"2014","unstructured":"Goodin DS (2014) The epidemiology of multiple sclerosis insights to disease pathogenesis. Handbook of Clinical Neurology. Elsevier, Amsterdam, pp 231\u2013266"},{"key":"11009_CR17","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s13075-018-1748-z","volume":"20","author":"YC Tien","year":"2018","unstructured":"Tien YC, Yen HH, Li CF et al (2018) Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative\/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: A prospective cohort study. Arthritis Res Ther 20:246. https:\/\/doi.org\/10.1186\/s13075-018-1748-z","journal-title":"Arthritis Res Ther"},{"key":"11009_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMOA1601277\/SUPPL_FILE\/NEJMOA1601277_DISCLOSURES.PDF","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376:221\u2013234. https:\/\/doi.org\/10.1056\/NEJMOA1601277\/SUPPL_FILE\/NEJMOA1601277_DISCLOSURES.PDF","journal-title":"N Engl J Med"},{"key":"11009_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMOA1606468\/SUPPL_FILE\/NEJMOA1606468_DISCLOSURES.PDF","volume":"18","author":"F Riederer","year":"2017","unstructured":"Riederer F (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. J fur Neurol Neurochir und Psychiatr 18:30\u201331. https:\/\/doi.org\/10.1056\/NEJMOA1606468\/SUPPL_FILE\/NEJMOA1606468_DISCLOSURES.PDF","journal-title":"J fur Neurol Neurochir und Psychiatr"},{"key":"11009_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/OFID\/OFY174","author":"DJ Epstein","year":"2018","unstructured":"Epstein DJ, Dunn J, Deresinski S (2018) Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management. Open Forum Infect Dis. https:\/\/doi.org\/10.1093\/OFID\/OFY174","journal-title":"Open Forum Infect Dis"}],"updated-by":[{"DOI":"10.1007\/s00415-022-11066-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000}}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11009-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11009-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11009-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T03:37:11Z","timestamp":1653017831000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11009-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["11009"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11009-x","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00415-022-11066-2","asserted-by":"object"}]},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]},"assertion":[{"value":"9 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00415-022-11066-2","URL":"https:\/\/doi.org\/10.1007\/s00415-022-11066-2","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was conducted according to 1964 Declaration of Helsinki and its later amendments. Approval from ethical committee was waived because of the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}